FDA Extends Routine Seafood Safety Paperwork
Published Date: 6/11/2026
Notice
Summary
The FDA is asking for approval to keep collecting info from seafood processors and importers to make sure fish products are safe using a system called HACCP. This affects anyone who processes or imports fish and requires them to keep records showing they’re following safety rules. Comments on this plan are open until July 13, 2026, and there’s no new cost, just a continuation of current paperwork.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
Estimated Annual Recordkeeping Burden: 1.93M Hours
FDA estimates the total annual recordkeeping burden for seafood HACCP activities is 1,930,264 hours. Examples from the estimate include 1,260,000 hours for documenting monitoring of critical control points (Sec. 123.6(c)(7)) and 65,600 hours for import verification activities (Sec. 123.12).
Seafood Processors Must Keep HACCP Records
If you process or import fish or fishery products, you must continue to collect and keep Hazard Analysis and Critical Control Point (HACCP) records under 21 CFR part 123. These records (for example, processing times, temperatures, acidity, monitoring logs) must be reviewed by trained employees and made available for FDA review as provided in Sec. 123.12(c).
No New Monetary Costs for Recordkeeping
FDA states there are no capital costs or operating and maintenance costs associated with this information collection; the submission is a reinstatement of current paperwork. The collection is described as a continuation of existing HACCP recordkeeping rather than adding new monetary costs.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-19181, Electronic Submission Template for Medical Device Premarket Approval Applications (PMAs); Draft Guidance for Industry and Food and Drug Administration Staff; Availability
The FDA just dropped a draft guide to help medical device makers submit their big approval applications electronically. This new template aims to make submissions easier, faster, and more consistent for companies working with the FDA’s device and biologics centers. If you’re in the medical device game, check it out and send your feedback by November 17, 2026—no fees or changes yet, just a heads-up for smoother future filings!
2026-19141, Target Animal Safety Evaluation for Veterinary Monoclonal Antibody Products; Draft Guidance for Industry; Availability
The FDA just released a draft guide to help vets and companies test the safety of special animal medicines called veterinary monoclonal antibodies. This new guide aims to make safety testing easier and more consistent worldwide, helping get these medicines to animals faster and safer. If you’re involved in making or testing these products, send your feedback by November 17, 2026, to shape the final rules!
2026-19166, Biosimilar User Fee Act III Future Needs in the Development of Interchangeable Products Post-Workshop; Draft Strategy Document
The FDA just shared a draft plan to help make interchangeable biosimilar drugs easier to develop and approve. This affects drug makers and patients who want more affordable medicine options. The FDA wants your feedback by November 17, 2026, before finalizing the plan, which supports innovation and smoother drug approvals through 2027.
Previous / Next Documents
Previous: 2026-11760, Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Establishment, Maintenance, and Availability of Records; Additional Traceability Records for Certain Foods
The FDA is asking for approval to collect extra records from food businesses that handle certain high-risk foods. This helps track food sources quickly to keep everyone safe. Food companies should get ready to keep and share these new records, and comments on this plan are due by July 13, 2026.
Next: 2026-11763, Cancellation of Previously Scheduled Open Meeting
The Equal Employment Opportunity Commission (EEOC) canceled its June 4, 2026 open meeting because the important decisions were already made by a vote on paper. This means no one needs to attend the meeting, but the new National Enforcement Plan for 2025-2029 and updated reporting instructions are still in effect. No extra costs or delays are expected from this change.